Human leukocyte antigen-G in cancer: Are they clinically relevant?

Cancer Letters

Volumn 311, Issue 2, 2011, Pages 123-130

  Yan, Wei Hua ^a  

^a TAIZHOU HOSPITAL OF ZHEJIANG PROVINCE   (China)

Author keywords

Diagnosis; HLA G; Immune escape; Malignancies; Prognosis

Indexed keywords

HLA G ANTIGEN;

DENDRITIC CELL; DISEASE COURSE; FETUS; HUMAN; IMMUNOLOGICAL TOLERANCE; MALIGNANT NEOPLASTIC DISEASE; NATURAL KILLER CELL; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SHORT SURVEY; T LYMPHOCYTE; TUMOR CELL; VIRUS INFECTION;

EID: 80053131814     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.07.019     Document Type: Review

References (89)

1. Schreiber R.D., Old L.J., Smyth M.J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011, 331:1565-1570.
2. Lampen M.H., van Hall T. Strategies to counteract MHC-I defects in tumors. Curr. Opin. Immunol. 2011, 23:293-298.
3. Chang C.C., Ferrone S. Immune selective pressure and HLA class I antigen defects in malignant lesions. Cancer Immunol. Immunother. 2007, 56:227-236.
4. Campoli M., Ferrone S. Tumor escape mechanisms: potential role of soluble HLA antigens and NK cells activating ligands. Tissue Antigens 2008, 72:321-334.
5. Carosella E.D., Moreau P., Lemaoult J., et al. HLA-G: from biology to clinical benefits. Trends Immunol. 2008, 29:125-132.
6. Larsen M.H., Hviid T.V. Human leukocyte antigen-G polymorphism in relation to expression, function, and disease. Hum. Immunol. 2009, 70:1026-1034.
7. LeMaoult J., Le Discorde M., Rouas-Freiss N., et al. Biology and functions of human leukocyte antigen-G in health and sickness. Tissue Antigens 2003, 62:273-284.
8. Park B., Lee S., Kim E., et al. The truncated cytoplasmic tail of HLA-G serves a quality-control function in post-ER compartments. Immunity 2001, 15:213-224.
9. Münz C., Nickolaus P., Lammert E., et al. The role of peptide presentation in the physiological function of HLA-G. Semin. Cancer Biol. 1999, 9:47-54.
10. Carosella E.D. The tolerogenic molecule HLA-G. Immunol. Lett. 2011, 138:22-24.
11. Paul P., Cabestre F.A., Ibrahim E.C., et al. Identification of HLA-G7 as a new splice variant of the HLA-G mRNA and expression of soluble HLA-G5, -G6, and -G7 transcripts in human transfected cells. Hum. Immunol. 2000, 61:1138-1149.
12. Park G.M., Lee S., Park B., et al. Soluble HLA-G generated by proteolytic shedding inhibits NK-mediated cell lysis. Biochem. Biophys. Res. Commun. 2004, 313:606-611.
13. Yie S.M., Hu Z. Human leukocyte antigen-G (HLA-G) as a marker for diagnosis, prognosis and tumor immune escape in human malignancies. Histol. Histopathol. 2011, 26:409-420.
14. Amiot L., Ferrone S., Grosse-Wilde H., et al. Biology of HLA-G in cancer: a candidate molecule for therapeutic intervention?. Cell. Mol. Life Sci. 2011, 68:417-431.
15. Clements C.S., Kjer-Nielsen L., McCluskey J., et al. Structural studies on HLA-G: implications for ligand and receptor binding. Hum. Immunol. 2007, 68:220-226.
16. Colonna M., Navarro F., Bellón T., et al. A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J. Exp. Med. 1997, 186:1809-1818.
17. Colonna M., Samaridis J., Cella M., et al. Human myelomonocytic cells express an inhibitory receptor for classical and nonclassical MHC class I molecules. J. Immunol. 1998, 160:3096-3100.
18. Rajagopalan S., Long E.O. A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells. J. Exp. Med. 1999, 189:1093-1100.
19. Chen L.J., Han Z.Q., Zhou H., et al. Inhibition of HLA-G expression via RNAi abolishes resistance of extravillous trophoblast cell line TEV-1 to NK lysis. Placenta 2010, 31:519-527.
20. Le Gal F.A., Riteau B., Sedlik C., et al. HLA-G-mediated inhibition of antigen-specific cytotoxic T lymphocytes. Int. Immunol. 1999, 11:1351-1356.
21. Kapasi K., Albert S.E., Yie S., et al. HLA-G has a concentration-dependent effect on the generation of an allo-CTL response. Immunology 2000, 101:191-200.
22. LeMaoult J., Krawice-Radanne I., Dausset J., et al. HLA-G1-expressing antigen-presenting cells induce immunosuppressive CD4+ T cells. Proc. Natl. Acad. Sci. USA 2004, 101:7064-7069.
23. Contini P., Ghio M., Poggi A., et al. Soluble HLA-A,-B,-C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation. Eur. J. Immunol. 2003, 33:125-134.
24. Carosella E.D., HoWangYin K.Y., Favier B., et al. HLA-G-dependent suppressor cells: diverse by nature, function, and significance. Hum. Immunol. 2008, 69:700-707.
25. Gros F., Cabillic F., Toutirais O., et al. Soluble HLA-G molecules impair natural killer/dendritic cell crosstalk via inhibition of dendritic cells. Eur. J. Immunol. 2008, 38:742-749.
26. Lesport E., Baudhuin J., Sousa S., et al. Inhibition of human Vγ9Vδ2 T-cell antitumoral activity through HLA-G: implications for immunotherapy of cancer. Cell. Mol. Life Sci. 2011, 10.1007/s00018-011-0632-7.
27. Ristich V., Zhang W., Liang S., et al. Mechanisms of prolongation of allograft survival by HLA-G/ILT4-modified dendritic cells. Hum. Immunol. 2007, 68:264-271.
28. Ristich V., Liang S., Zhang W., et al. Tolerization of dendritic cells by HLA-G. Eur. J. Immunol. 2005, 35:1133-1142.
29. Selmani Z., Naji A., Zidi I., et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25 highFOXP3+ regulatory T cells. Stem Cells 2008, 26:212-222.
30. Agaugué S., Carosella E.D., Rouas-Freiss N. Role of HLA-G in tumor escape through expansion of myeloid-derived suppressor cells and cytokinic balance in favor of Th2 versus Th1/Th17. Blood 2011, 117:7021-7031.
31. Wiendl H., Mitsdoerffer M., Hofmeister V., et al. A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape. J. Immunol. 2002, 168:4772-4780.
32. Morandi F., Levreri I., Bocca P., et al. Human neuroblastoma cells trigger an immunosuppressive program in monocytes by stimulating soluble HLA-G release. Cancer Res. 2007, 67:6433-6441.
33. Malmberg K.J., Levitsky V., Norell H., et al. IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism. J. Clin. Invest. 2002, 110:1515-1523.
34. Menier C., Riteau B., Carosella E.D., et al. MICA triggering signal for NK cell tumor lysis is counteracted by HLA-G1-mediated inhibitory signal. Int. J. Cancer 2002, 100:63-70.
35. Rouas-Freiss N., Moreau P., Ferrone S., et al. HLA-G proteins in cancer, do they provide tumor cells with an escape mechanism?. Cancer Res. 2005, 65:10139-10144.
36. Joly E., Hudrisier D. What is trogocytosis and what is its purpose?. Nat. Immunol. 2003, 4:815.
37. Caumartin J., Favier B., Daouya M., et al. Trogocytosis-based generation of suppressive NK cells. Embo. J. 2007, 26:1423-1433.
38. HoWangYin K.Y., Alegre E., Daouya M., et al. Different functional outcomes of intercellular membrane transfers to monocytes and T cells. Cell. Mol. Life Sci. 2010, 67:1133-1145.
39. LeMaoult J., Caumartin J., Daouya M., et al. Immune regulation by pretenders, cell-to-cell transfers of HLA-G make effector T cells act as regulatory cells. Blood 2007, 109:2040-2048.
40. Paul P., Rouas-Freiss N., Khalil-Daher I., et al. HLA-G expression in melanoma, a way for tumor cells to escape from immunosurveillance. Proc. Natl. Acad. Sci. USA 1998, 95:4510-4515.
41. Yan W.H. HLA-G expression in hematologic malignancies. Expert Rev. Hematol. 2010, 3:67-80.
42. Yan W.H. HLA-G expression in cancers: potential role in diagnosis, prognosis and therapy. Endocr. Metab. Immune Disord. Drug Targets 2011, 11:76-89.
43. Riteau B., Faure F., Menier C., et al. Exosomes bearing HLA-G are released by melanoma cells. Hum. Immunol. 2003, 64:1064-1072.
44. Goldman-Wohl D., Ariel I., Greenfield C., et al. A study of human leukocyte antigen G expression in hydatidiform moles. Am. J. Obstet. Gynecol. 2001, 185:476-480.
45. Anastassiou G., Rebmann V., Wagner S., et al. Expression of classic and nonclassic HLA class I antigens in uveal melanoma. Invest. Ophthalmol. Vis. Sci. 2003, 44:2016-2019.
46. Hurks H.M., Valter M.M., Wilson L., et al. Uveal melanoma, no expression of HLA-G. Invest. Ophthalmol. Vis. Sci. 2001, 42:3081-3084.
47. Paul P., Cabestre F.A., Le Gal F.A., et al. Heterogeneity of HLA-G gene transcription and protein expression in malignant melanoma biopsies. Cancer Res. 1999, 59:1954-1960.
48. Ibrahim C., Aractingi S., Allory Y., et al. Analysis of HLA antigen expression in benign and malignant melanocytic lesions reveals that upregulation of HLA-G expression correlates with malignant transformation; high inflammatory infiltration and HLA-A1 genotype. Int. J. Cancer 2004, 108:243-250.
49. Jung Y.W., Kim Y.T., Kim S.W., et al. Correlation of human leukocyte antigen-G (HLA-G) expression and disease progression in epithelial ovarian cancer. Reprod. Sci. 2009, 16:1103-1111.
50. Menier C., Prevot S., Carosella E.D., et al. Human leukocyte antigen-G is expressed in advanced-stage ovarian carcinoma of high-grade histology. Hum. Immunol. 2009, 70:1006-1009.
51. Kleinberg L., Flørenes V.A., Skrede M., et al. Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma. Virchows Arch. 2006, 449:31-39.
52. He X., Dong D.D., Yie S.M., et al. HLA-G expression in human breast cancer, implications for diagnosis and prognosis; and effect on allocytotoxic lymphocyte response after hormone treatment in vitro. Ann. Surg.Oncol. 2010, 17:1459-1469.
53. de Kruijf E.M., Sajet A., van Nes J.G., et al. HLA-E and HLA-G expression in classical HLA class I-negative tumors is of prognostic value for clinical outcome of early breast cancer patients. J. Immunol. 2010, 185:7452-7459.
54. Lin A., Chen H.X., Zhu C.C., et al. Aberrant human leukocyte antigen-G expression and its clinical relevance in hepatocellular carcinoma. J. Cell. Mol. Med. 2010, 14:2162-2171.
55. Cai M.Y., Xu Y.F., Qiu S.J., et al. Human leukocyte antigen-G protein expression is an unfavorable prognostic predictor of hepatocellular carcinoma following curative resection. Clin. Cancer Res. 2009, 15:4686-4693.
56. Wang Y., Ye Z., Meng X.Q., et al. Expression of HLA-G in patients with hepatocellular carcinoma. Hepatobiliary Pancreat. Dis. Int. 2011, 10:158-163.
57. Lin A., Zhu C.C., Chen H.X., et al. Clinical relevance and functional implications for human leukocyte antigen-G expression in non-small-cell lung cancer. J. Cell. Mol. Med. 2010, 14:2318-2329.
58. Yie S.M., Yang H., Ye S.R., et al. Expression of human leucocyte antigen G (HLA-G) is associated with prognosis in non-small cell lung cancer. Lung Cancer 2007, 58:267-274.
59. Yie S.M., Yang H., Ye S.R., et al. Expression of human leukocyte antigen G (HLA-G) correlates with poor prognosis in gastric carcinoma. Ann. Surg. Oncol. 2007, 14:2721-2729.
60. Ye S.R., Yang H., Li K., et al. Human leukocyte antigen G expression, as a significant prognostic indicator for patients with colorectal cancer. Mod. Pathol. 2007, 20:375-383.
61. Yie S.M., Yang H., Ye S.R., et al. Expression of HLA-G is associated with prognosis in esophageal squamous cell carcinoma. Am. J. Clin. Pathol. 2007, 128:1002-1009.
62. Lin A., Zhang X., Zhou W.J., et al. HLA-G expression is associated with a poor prognosis in patients with esophageal squamous cell carcinoma. Int. J. Cancer 2011, 129:1382-1390.
63. Barrier B.F., Kendall B.S., Sharpe-Timms K.L., et al. Characterization of human leukocyte antigen-G (HLA-G) expression in endometrial adenocarcinoma. Gynecol. Oncol. 2006, 103:25-30.
64. Bijen C.B., Bantema-Joppe E.J., de Jong R.A., et al. The prognostic role of classical and nonclassical MHC class I expression in endometrial cancer. Int. J. Cancer 2010, 126:1417-1427.
65. Bukur J., Rebmann V., Grosse-Wilde H., et al. Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma. Cancer Res. 2003, 63:4107-4111.
66. Ibrahim E.C., Allory Y., Commo F., et al. Altered pattern of major histocompatibility complex expression in renal carcinoma, tumor-specific expression of the nonclassical human leukocyte antigen-G molecule is restricted to clear cell carcinoma while up-regulation of other major histocompatibility complex antigens is primarily distributed in all subtypes of renal carcinoma. Am. J. Pathol. 2003, 162:501-508.
67. Ibrahim E.C., Guerra N., Lacombe M.J., et al. Tumor-specific up-regulation of the nonclassical class I HLA-G antigen expression in renal carcinoma. Cancer Res. 2001, 61:6838-6845.
68. Li B.L., Lin A., Zhang X.J., et al. Characterization of HLA-G expression in renal cell carcinoma. Tissue Antigens 2009, 74:213-221.
69. Gan L.H., Huang L.F., Zhang X., et al. Tumor-specific upregulation of human leukocyte antigen-G expression in bladder transitional cell carcinoma. Hum. Immunol. 2010, 71:899-904.
70. El-Chennawi F.A., Auf F.A., El-Diasty A.M., et al. Expression of HLA-G in cancer bladder. Egypt. J. Immunol. 2005, 12:57-64.
71. Yan W.H., Lin A., Chen B.G., et al. Unfavourable clinical implications for HLA-G expression in acute myeloid leukaemia. J. Cell. Mol. Med. 2008, 12:889-898.
72. Guo Q.Y., Chen B.G., Ruan Y.Y., et al. HLA-G expression is irrelevant to prognosis in patients with acute myeloid leukemia. Leuk. Res. 2011, 10.1016/j.leukres.2011.05.036.
73. Nückel H., Rebmann V., Dürig J., et al. HLA-G expression is associated with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukemia. Blood 2005, 105:1694-1698.
74. Erikci A.A., Karagoz B., Ozyurt M., et al. HLA-G expression in B chronic lymphocytic leukemia, a new prognostic marker?. Hematology 2009, 14:101-105.
75. Perez-Chacon G., Rosado S., Rebolleda N., et al. Prognostic irrelevance of HLA-G in B-cell chronic lymphocytic leukemia. Int. J. Lab. Hematol. 2009, 31:327-337.
76. Giannopoulos K., Dmoszyńska A., Bojarska-Junak A., et al. Expression of HLA-G in patients with B-cell chronic lymphocytic leukemia (B-CLL), Folia. Histochem. Cytobiol. 2008, 46:457-460.
77. Moreau P., Flajollet S., Carosella E.D. Non-classical transcriptional regulation of HLA-G: an update. J. Cell. Mol. Med. 2009, 13:2973-2989.
78. Rebmann V., Busemann A., Lindemann M., et al. Detection of HLA-G5 secreting cells. Hum. Immunol. 2003, 64:1017-1024.
79. Singer G., Rebmann V., Chen Y.C., et al. HLA-G is a potential tumor marker in malignant ascites. Clin. Cancer Res. 2003, 9:4460-4464.
80. Mach P., Blecharz P., Basta P., et al. Differences in the soluble HLA-G blood serum concentration levels in patients with ovarian cancer and ovarian and deep endometriosis. Am. J. Reprod. Immunol. 2010, 63:387-395.
81. Chen H.X., Lin A., Shen C.J., et al. Upregulation of human leukocyte antigen-G expression and its clinical significance in ductal breast cancer. Hum. Immunol. 2010, 71:892-898.
82. Schütt P., Schütt B., Switala M., et al. Prognostic relevance of soluble human leukocyte antigen-G and total human leukocyte antigen class I molecules in lung cancer patients. Hum. Immunol. 2010, 71:489-495.
83. Zhu C.B., Wang C.X., Zhang X., et al. Serum sHLA-G levels, a useful indicator in distinguishing colorectal cancer from benign colorectal diseases. Int. J. Cancer 2011, 128:617-622.
84. Cao M., Yie S.M., Liu J., et al. Plasma soluble HLA-G is a potential biomarker for diagnosis of colorectal, gastric, esophageal and lung cancer. Tissue Antigens 2011, 78:120-128.
85. Zheng N., Wang C.X., Zhang X., et al. Up-regulation of HLA-G expression in cervical premalignant and malignant lesions. Tissue Antigens 2011, 77:218-224.
86. Leleu X., Le Friec G., Facon T., et al. Total soluble HLA class I and soluble HLA-G in multiple myeloma and monoclonal gammopathy of undetermined significance. Clin. Cancer Res. 2005, 11:7297-7303.
87. Sebti Y., Le Maux A., Gros F., et al. Expression of functional soluble human leucocyte antigen-G molecules in lymphoproliferative disorders. Brit. J. Haematol. 2007, 138:202-212.
88. Amiot L., Onno M., Drénou B., et al. HLA-G class I gene expression in normal and malignant hematopoietic cells. Hum. Immunol. 1998, 59:524-528.
89. Yong P., Kim S.J., Lee S.J., et al. Serum level of soluble human leukocyte antigen-G molecules in non-Hodgkin lymphoma, does it have a prognostic value?. Leuk. Lymphoma 2008, 49:1623-1626.